Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab
Here, the authors identify B lymphocyte antigen CD20 as a marker for HIV-infected T cells and provide evidence for the potential use of anti-CD20 antibodies in combination with latency reversing agents for depletion of viral reactivated CD4 T cells in patients on antiretroviral therapy.
Guardado en:
Autores principales: | Carla Serra-Peinado, Judith Grau-Expósito, Laura Luque-Ballesteros, Antonio Astorga-Gamaza, Jordi Navarro, Jenny Gallego-Rodriguez, Mario Martin, Adrià Curran, Joaquin Burgos, Esteban Ribera, Berta Raventós, Rein Willekens, Ariadna Torrella, Bibiana Planas, Rosa Badía, Felipe Garcia, Josep Castellví, Meritxell Genescà, Vicenç Falcó, Maria J. Buzon |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/704040ec0d7d48cf90855591b8bb7358 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4<sup>+</sup> T cells as a Major Niche for HIV-1 Transcription in HIV-Infected Patients
por: Judith Grau-Expósito, et al.
Publicado: (2017) -
Peripheral and lung resident memory T cell responses against SARS-CoV-2
por: Judith Grau-Expósito, et al.
Publicado: (2021) -
Resident memory T cells are a cellular reservoir for HIV in the cervical mucosa
por: Jon Cantero-Pérez, et al.
Publicado: (2019) -
Rituximab for refractory granulomatous eye disease
por: Lower EE, et al.
Publicado: (2012) -
The potential effect of statins on rituximab immunotherapy.
por: Mark S Cragg
Publicado: (2008)